


REMARKS

Applicants elect the invention of Group I and the species of immunomodulatory proteins and chemotherapy, with traverse. Applicants respectfully request reconsideration of the requirement in light of the present amendment to claim 1. As is noted above, this claim has been amended to specify that the method is for preventing or treating metastasis of cancer. This feature is not disclosed or suggested in the document cited by the Office. Thus, Applicants submit that the special technical feature linking the present claims is the prevention or treatment of cancer metastasis, and that this technical feature defines a contribution over the prior art. The claims currently separated into Groups I and II should therefore be examined together in this application.

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. Although no charges are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 14, 2005


Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045